- Home
- INCR vs NSPR Comparison
INCR vs NSPR Comparison
Compare INCR & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- NSPR
- Stock Information
- Founded
- INCR 1994
- NSPR 2005
- Country
- INCR Israel
- NSPR United States
- Employees
- INCR N/A
- NSPR N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- NSPR Medical/Dental Instruments
- Sector
- INCR Health Care
- NSPR Health Care
- Exchange
- INCR Nasdaq
- NSPR Nasdaq
- Market Cap
- INCR 76.7M
- NSPR 79.7M
- IPO Year
- INCR N/A
- NSPR N/A
- Fundamental
- Price
- INCR $1.48
- NSPR $2.59
- Analyst Decision
- INCR
- NSPR Strong Buy
- Analyst Count
- INCR 0
- NSPR 2
- Target Price
- INCR N/A
- NSPR $4.75
- AVG Volume (30 Days)
- INCR 19.9K
- NSPR 45.6K
- Earning Date
- INCR 05-06-2025
- NSPR 05-09-2025
- Dividend Yield
- INCR N/A
- NSPR N/A
- EPS Growth
- INCR N/A
- NSPR N/A
- EPS
- INCR N/A
- NSPR N/A
- Revenue
- INCR $72,420,918.00
- NSPR $7,009,000.00
- Revenue This Year
- INCR N/A
- NSPR $28.93
- Revenue Next Year
- INCR $39.30
- NSPR $172.18
- P/E Ratio
- INCR N/A
- NSPR N/A
- Revenue Growth
- INCR N/A
- NSPR 12.96
- 52 Week Low
- INCR $1.17
- NSPR $1.87
- 52 Week High
- INCR $3.72
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- INCR 57.35
- NSPR 45.62
- Support Level
- INCR $1.32
- NSPR $2.37
- Resistance Level
- INCR $1.31
- NSPR $2.68
- Average True Range (ATR)
- INCR 0.07
- NSPR 0.12
- MACD
- INCR 0.03
- NSPR 0.01
- Stochastic Oscillator
- INCR 96.30
- NSPR 80.39
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.